Introduction Antiseizure medications (ASMs) are the backbone of epilepsy treatment, offering seizure control in approximately 70% of patients when the therapy is appropriately selected (1). With nearly 30 ASMs available, choosing the right medication, whether for monotherapy, adjunctive use, or initial treatment, requires careful consideration of b

Introduction Epilepsy is characterized by recurrent seizures, remaining a significant neurological concern in older adults, with a prevalence of ~1.5% in individuals aged ≥65 years (1). Focal onset seizures with impaired awareness predominated in this group (1). Management requires a tailored approach due to age-related physiological changes, comor

Introduction: Multiple Sclerosis (MS) is a chronic inflammatory autoimmune disorder of the central nervous system that primarily affects young adults but can also occur in children (1). Pediatric-onset MS (POMS) exhibits distinct clinical and radiological features compared to adult-onset MS and often follows a different disease course (1). Case pre

Despite strong evidence supporting non‑opioid modalities, real-world practice continues to show critical unmet needs in specific patient populations. For post‑operative pain among opioid‑sensitive individuals, a systematic review and network meta‑analysis of 23,902 patients demonstrated that IV lidocaine (OR 0.32), ketamine (OR 0.64), and gabapenti

Suzetrigine (Journavx) is an oral, selective Naᵥ1.8 sodium‑channel inhibitor approved by the FDA on January 30, 2025, for moderate-to-severe acute pain (1). It acts peripherally on Naᵥ1.8 channels in nociceptive neurons, avoiding central nervous system side effects associated with opioids (2). Two phase III randomized, double-blind trials in post‑b

Introduction Gaucher disease type 3 (GD3) is a genetic, progressive lysosomal storage disorder characterized by visceral manifestations and chronic neurologic symptoms including horizontal ophthalmoplegia/supranuclear gaze palsy, ataxia and dystonia (1). Existing therapies like enzyme replacement (ERT) and substrate reduction therapy (SRT) are effe

Introduction Myasthenia Gravis (MG) is a chronic autoimmune neuromuscular disorder caused by autoantibodies targeting components of the neuromuscular junction, particularly the acetylcholine receptor (AChR). These antibodies impair neuromuscular transmission, resulting in fluctuating muscle weakness and fatigue. While immunosuppressive agents such

Introduction Myasthenia Gravis (MG) is a chronic autoimmune neuromuscular disorder characterized by fluctuating muscle weakness and fatigue. It primarily results from autoantibodies that target components of the neuromuscular junction, particularly the acetylcholine receptor (AChR), leading to impaired signal transmission between nerves and muscles

Introduction: Pediatric multiple sclerosis (MS) is a chronic autoimmune demyelinating disorder of the central nervous system that presents unique challenges in diagnosis and management due to its early onset and potential impact on neurological development (1). While fingolimod is currently approved for treating pediatric MS and has demonstrated ef